Live
- After caste census, Dalits, tribals, poor will recognise their true strength: Rahul Gandhi
- Who was Birsa Munda, whose 'Ulgulan' declared the end of British rule in Jharkhand?
- Five selected as Indian Rhodes Scholars for 2025
- Raj Thackeray releases MNS election Manifesto with a ‘key’ to implementing it
- COP29: 3 methodologies approved for issuing high-integrity carbon credits
- MP: Celebrations of Birsa Munda's birth anniversary begin in presence of Guv, CM in Shahdol
- NGT seeks details of waste to energy plants not complying with norms
- Dev Deepawali 2024: Significance, Rituals, and How to Celebrate with Lamps
- Air quality in Kolkata dips to ‘very unhealthy’ category
- Air pollution may raise risk of lung cancer, asthma in children, say experts
Covaxin booster effective against Omicron, Delta
Representational Image
Says Bharat Bio citing US study
New Delhi: Hyderabad-based biotechnology firm Bharat Biotech on Wednesday said a booster shot of its Covid-19 vaccine Covaxin will neutralise both Omicron and Delta variants of Covid-19.
Booster dose of Covaxin generated robust neutralising antibody responses against both Omicron and Delta variants of SARS-CoV-2, Bharat Biotech said. The study was conducted at the Emory Vaccine Center in Atlanta based on blood serum collected from 13 individuals, 28 days after their booster shot. It was sponsored by Bharat Biotech's partner Ocugen Inc.
"The neutralisation activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant," Bharat Biotech said in a statement. "More than 90% of all individuals boosted with Covaxin showed neutralising antibodies."
Bharat Biotech had earlier said trials have indicated that its vaccine Covaxin is safe for booster dosage against Covid-19. The Hyderabad-based company had announced the results on the safety and immunogenicity of COVAXIN (BBV152).
The analysis showed, six months after a two-dose Covaxin (BBV152) vaccination series cell-mediated immunity and neutralising antibodies to both homologous (D614G) and heterologous strains (Alpha, Beta, Delta, and Delta plus) persisted above baseline, although the magnitude of the responses had declined, the company said.
Furthermore, neutralising antibodies against homologous and heterologous SARS-CoV-2 variants increased from 19 to 265 folds after a third vaccination, it said.
Booster BBV152 vaccination is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections, it said. "These trial results provide a strong foundation towards our goal to provide Covaxin as a booster dose. Our goal of developing a global vaccine against Covid-19 has been achieved with Covaxin indicated for adults, children, two dose primary and booster doses. This enables use of the vaccine as a universal vaccine," Bharat Biotech Chairman and Managing Director Krishna Ella said.
